|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100049127 |
|
最近更新日期: Date of Last Refreshed on: |
2022-02-27 17:04:28 |
|
注册时间: Date of Registration: |
2021-07-21 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
槐杞黄颗粒治疗儿童原发性免疫性血小板减少症(气阴两虚)疗效与安全性的登记注册研究 |
|
Public title: |
A registration study on the efficacy and safety of Huaiqihuang granules in the treatment of children with primary immune thrombocytopenia (deficiency of Qi and Yin) |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
槐杞黄颗粒治疗儿童原发性免疫性血小板减少症(气阴两虚)疗效与安全性的开放、多中心、登记注册研究 |
|
Scientific title: |
An open, multicenter, registration study on the efficacy and safety of Huaiqihuang granules in the treatment of children with primary immune thrombocytopenia (deficiency of Qi and Yin) |
|
研究课题代号(代码): Study subject ID: |
HQH-201703.02 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
ChiMCTR2100005129 |
|
申请注册联系人: |
陆永辉 |
研究负责人: |
金润铭 |
|
Applicant: |
Lu Yonghui |
Study leader: |
Jin Runming |
|
申请注册联系人电话: Applicant telephone: |
+86 13801462500 |
研究负责人电话:
Study leader's |
+86 27 85726762 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lyh307@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
jinrunm@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
http://www.gaitianli.com.cn/ |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
江苏省启东市经济技术开发区南苑西路1166号 |
研究负责人通讯地址: |
湖北省武汉市江汉区解放大道1277号 |
|
Applicant address: |
1166 Nanyuan Road West, Economic and Technological Development Zone, Qidong, Jiangsu |
Study leader's address: |
1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei |
|
申请注册联系人邮政编码: Applicant postcode: |
226200 |
研究负责人邮政编码: Study leader's postcode: |
430022 |
|
申请人所在单位: |
启东盖天力药业有限公司 |
||
|
Applicant's institution: |
Qidong Gaitianli Pharmaceutical Co. LTD |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属协和医院 |
||
|
Affiliation of the Leader: |
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2017]伦审字(S270)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2017-10-25 00:00:00 | ||
|
伦理委员会联系人: |
陈汇 |
||
|
Contact Name of the ethic committee: |
Chen Hui |
||
|
伦理委员会联系地址: |
湖北省武汉市硚口区航空路13号 |
||
|
Contact Address of the ethic committee: |
13 Hangkong Road, Qiaokou District, Wuhan, Hubei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 83691785 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
tongjilunli@163.com |
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属协和医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市江汉区解放大道1277号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
启东盖天力药业有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Qidong Gaitianli Pharmaceutical Co. LTD |
||||||||||||||||||||||
|
研究疾病: |
儿童原发性免疫性血小板减少症 |
||||||||||||||||||||||
|
Target disease: |
primary immune thrombocytopenia in children |
||||||||||||||||||||||
|
研究疾病代码: |
ICD-10: D69.402 |
||||||||||||||||||||||
|
Target disease code: |
ICD-10: D69.402 |
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
析因分组(即根据危险因素或暴露因素分组) |
||||||||||||||||||||||
|
Study design: |
Factorial |
||||||||||||||||||||||
|
研究目的: |
对槐杞黄颗粒治疗儿童原发性免疫性血小板减少症(气阴两虚)的临床疗效及安全性进行评价。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of Huaiqihuang granules in the treatment of children with primary immune thrombocytopenia (deficiency of Qi and Yin). |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
本研究为观察性注册登记研究,不干预患者的治疗用药,不规定具体的试验药物。根据试验目的,收集患者治疗信息(槐杞黄颗粒、ITP相关治疗药物和合并疾病用药)。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
This study is an observational registration study, with no intervention in the treatment of patients, and no experimental drugs are specified. According to the purpose of the study, the treatment information of patients (Huaiqihuang granules, ITP-related therapeutic drugs and drugs for complicated diseases) was collected. |
||||||||||||||||||||||
|
纳入标准: |
1.1月<=年龄<=14岁,性别不限; |
||||||||||||||||||||||
|
Inclusion criteria |
(1) 1 month <= age <= 14 years old, gender is not limited. |
||||||||||||||||||||||
|
排除标准: |
1.先天性血小板减少症患儿; |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Children with congenital thrombocytopenia; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2017-07-10 00:00:00至 To 2024-12-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2018-03-30 00:00:00 至 To 2021-12-19 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan 临床试验公共管理平台, http://www.medresman.org.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
ResMan, http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用电子化数据管理系统,由数据管理员根据研究方案、病例登记表构建电子病例报告表(eCRF),数据管理员根据研究者、监查员、稽查员等不同身份分别创建账号,授予不同权限访问EDC系统。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
In this study, an Electronic Data Capture System (EDC) was adopted. Data administrators constructed electronic case report form (eCRF) according to the research protocol and case registration form. Data administrators created accounts according to different identities such as researchers, clinical research associates and inspectors, and granted different permissions to access the EDC system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |